Regencell Bioscience Holdings Limited (RGC) 10-Year Financial Performance & Capital Metrics

RGC • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

AboutRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Show more

Revenue $0
EBITDA -$4M +27.5%
Net Income -$4M +26.7%
EPS (Diluted) -0.01 +26.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -42.58% -5.4%
ROIC -43.77% -3.8%
Debt/Equity 0.01 -73.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Trading more than 30% below 52-week high
✗Expensive at 1957.8x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM58.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-565.15%

ROCE

10Y Avg-1001.51%

5Y Avg-1001.51%

3Y Avg-67.56%

Latest-46.76%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.19B	132.26	40.20	24.81%	15.95%	14.25%	4.23%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.95B	51.45	38.98	8.94%	-2.8%	-1.82%	5.8%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	28.55M	7.43	-0.59			-379.78%		0.08
AYTUAytu BioPharma, Inc.	26.79M	2.63	-1.22	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	417.25M	3.42	-6.71	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.48	-42.12	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	16.09B	32.54	-3740.23			-67.02%		0.01

Profit & Loss

	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	9.52K	26.46K	604.4K	769.69K	745.59K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-9.52K	-26.46K	-604.4K	-769.69K	-745.59K
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-1.78%	-21.85%	-0.27%	0.03%
Operating Expenses+	390.99K	812.37K	1.38M	7.62M	6.27M	3.99M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	162.77K	426.14K	943.04K	5.11M	4.69M	2.92M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	228.22K	386.23K	438.32K	2.51M	1.58M	1.07M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-390.99K	-812.37K	-1.38M	-7.62M	-6.27M	-4.74M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-1.08%	-0.7%	-4.51%	0.18%	0.24%
EBITDA+	0	-802.86K	-1.35M	-7.01M	-5.5M	-3.99M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-0.69%	-4.18%	0.22%	0.27%
D&A (Non-Cash Add-back)	390.99K	9.52K	26.46K	604.4K	769.69K	745.59K
EBIT	-390.99K	-812.37K	-1.38M	-7.62M	-6.06M	-4.36M
Net Interest Income+	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0
Other Income/Expense	0	0	34.62K	23.21K	211.34K	373.5K
Pretax Income+	-390.99K	-812.37K	-1.35M	-7.59M	-6.06M	-4.36M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	-391	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	0.97%	0.99%
Net Income+	-390.99K	-812.37K	-1.35M	-7.42M	-5.87M	-4.3M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-1.08%	-0.66%	-4.51%	0.21%	0.27%
Net Income (Continuing)	-390.99K	-812.37K	-1.35M	-7.59M	-6.06M	-4.36M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	15.39K	-40.9K	0
EPS (Diluted)+	-0.00	-0.00	-0.00	-0.02	-0.01	-0.01
EPS Growth %	-	-	-	-	0.21%	0.27%
EPS (Basic)	-0.00	-0.00	-0.00	-0.02	-0.01	-0.01
Diluted Shares Outstanding	480.4M	480.4M	480.4M	494.49M	494.49M	494.49M
Basic Shares Outstanding	480.4M	480.4M	480.4M	494.49M	494.49M	494.49M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Total Current Assets+	243.31K	386.98K	66.85K	16.44M	11.62M	8.11M
Cash & Short-Term Investments	243.31K	386.98K	59.41K	16.42M	11.56M	7.96M
Cash Only	243.31K	386.98K	59.41K	6.42M	1.56M	2.96M
Short-Term Investments	0	0	0	10M	10M	5M
Accounts Receivable	0	0	7.44K	27.6K	56.55K	152.78K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	-27.6K	-56.55K	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	-7.44K	0	0	0
Total Non-Current Assets+	0	127.04K	273.29K	1.57M	1M	324.2K
Property, Plant & Equipment	0	108.32K	81.86K	1.46M	891.91K	226.51K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	18.72K	191.42K	114.3K	108.5K	97.68K
Total Assets+	243.31K	514.02K	340.13K	18.02M	12.62M	8.44M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	1.11%	-0.34%	51.98%	-0.3%	-0.33%
Total Current Liabilities+	2.08M	3.16M	4.34M	577.76K	606.91K	193.58K
Accounts Payable	0	0	0	0	0	0
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	2.08M	3.07M	3.68M	410.99K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	0	0	-410.99K	0	0
Current Ratio	0.12x	0.12x	0.02x	28.46x	19.15x	41.92x
Quick Ratio	0.12x	0.12x	0.02x	28.51x	19.24x	41.92x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	360.27K	25.41K	25.93K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	360.27K	25.41K	25.93K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	2.08M	3.16M	4.34M	938.03K	632.32K	219.51K
Total Debt+	2.08M	3.07M	3.68M	771.25K	463.67K	85.74K
Net Debt	1.84M	2.68M	3.62M	-5.65M	-1.1M	-2.88M
Debt / Equity	-	-	-	0.05x	0.04x	0.01x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	-1.84M	-2.65M	-4M	17.08M	11.99M	8.22M
Equity Growth %	-	-0.44%	-0.51%	5.27%	-0.3%	-0.31%
Book Value per Share	-0.00	-0.01	-0.01	0.03	0.02	0.02
Total Shareholders' Equity	-1.84M	-2.65M	-4M	17.07M	12.03M	8.22M
Common Stock	100	100	100	130	130	130
Retained Earnings	-1.84M	-2.65M	-4M	-11.44M	-17.32M	-21.62M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-86.66K	-45.77K
Minority Interest	0	0	0	15.39K	-40.9K	0

Cash Flow

	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024
Cash from Operations+	-390.99K	-726.57K	-767.31K	-5.27M	-4.96M	-4M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.86%	-0.06%	-5.86%	0.06%	0.19%
Net Income	-390.99K	-812.37K	-1.35M	-7.45M	-5.87M	-4.36M
Depreciation & Amortization	0	9.52K	26.46K	604.4K	769.69K	745.59K
Stock-Based Compensation	0	0	0	2.76M	930K	449.31K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	0	0	0	-159.34K	-282.56K	-248K
Working Capital Changes	0	76.28K	552.98K	-1.02M	-508.94K	-585.37K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0
Cash from Investing+	0	-117.84K	0	-10.78M	58.98K	5.24M
Capital Expenditures	0	-117.84K	0	-780.88K	-27.39K	-5.38K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-10M	86.37K	0
Cash from Financing+	480.99K	988.08K	439.75K	22.41M	134.91K	102.28K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	988.08K	439.75K	22.41M	134.91K	102.28K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-390.99K	-844.41K	-767.31K	-6.05M	-4.99M	-4.01M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-1.16%	0.09%	-6.88%	0.17%	0.2%
FCF per Share	-0.00	-0.00	-0.00	-0.01	-0.01	-0.01
FCF Conversion (FCF/Net Income)	1.00x	0.89x	0.57x	0.71x	0.85x	0.93x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-113.47%	-40.39%	-42.58%
Return on Invested Capital (ROIC)	-	-3803.35%	-	-103.31%	-42.16%	-43.77%
Debt / Equity	-	-	-	0.05x	0.04x	0.01x
FCF Conversion	1.00x	0.89x	0.57x	0.71x	0.85x	0.93x

Frequently Asked Questions

Growth & Financials

Regencell Bioscience Holdings Limited (RGC) grew revenue by 0.0% over the past year. Growth has been modest.

Regencell Bioscience Holdings Limited (RGC) reported a net loss of $4.5M for fiscal year 2024.

Dividend & Returns

Regencell Bioscience Holdings Limited (RGC) has a return on equity (ROE) of -42.6%. Negative ROE indicates the company is unprofitable.

Regencell Bioscience Holdings Limited (RGC) had negative free cash flow of $6.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener